David Westenberg
Stock Analyst at Piper Sandler
(4.02)
# 532
Out of 4,896 analysts
162
Total ratings
50%
Success rate
12.21%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WGS GeneDx Holdings | Initiates: Overweight | $110 | $82.56 | +33.24% | 1 | Jul 9, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $55 → $70 | $56.88 | +23.07% | 4 | May 15, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2 → $1.25 | $1.47 | -14.97% | 8 | May 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $205 → $210 | $160.43 | +30.90% | 15 | May 15, 2025 | |
| ILMN Illumina | Maintains: Overweight | $190 → $185 | $99.25 | +86.40% | 16 | May 15, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $205 → $210 | $154.96 | +35.52% | 14 | May 12, 2025 | |
| LH Labcorp Holdings | Maintains: Neutral | $260 → $280 | $249.62 | +12.17% | 4 | May 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $18 → $12 | $7.26 | +65.29% | 9 | May 6, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $60 | $50.25 | +19.40% | 9 | May 6, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $16 → $23 | $19.27 | +19.36% | 8 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $11.82 | +9.98% | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $168.09 | +18.98% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $5.39 | -7.24% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $12 | $14.90 | -19.46% | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $3.44 | +132.56% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $51.91 | +34.85% | 10 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $435 → $510 | $533.37 | -4.38% | 10 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $12.80 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $30.34 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $49.64 | - | 1 | Nov 21, 2017 |
GeneDx Holdings
Jul 9, 2025
Initiates: Overweight
Price Target: $110
Current: $82.56
Upside: +33.24%
Tempus AI
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $56.88
Upside: +23.07%
Pacific Biosciences of California
May 15, 2025
Maintains: Neutral
Price Target: $2 → $1.25
Current: $1.47
Upside: -14.97%
Natera
May 15, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $160.43
Upside: +30.90%
Illumina
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $99.25
Upside: +86.40%
Zoetis
May 12, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $154.96
Upside: +35.52%
Labcorp Holdings
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $249.62
Upside: +12.17%
NeoGenomics
May 6, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $7.26
Upside: +65.29%
Guardant Health
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $50.25
Upside: +19.40%
Fulgent Genetics
May 6, 2025
Maintains: Neutral
Price Target: $16 → $23
Current: $19.27
Upside: +19.36%
May 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $11.82
Upside: +9.98%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $168.09
Upside: +18.98%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $5.39
Upside: -7.24%
Mar 6, 2025
Maintains: Neutral
Price Target: $16 → $12
Current: $14.90
Upside: -19.46%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.44
Upside: +132.56%
Feb 26, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $51.91
Upside: +34.85%
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $533.37
Upside: -4.38%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $12.80
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $30.34
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $49.64
Upside: -